Day One Biopharmaceuticals Inc (DAWN)vsInsmed Inc (INSM)
DAWN
Day One Biopharmaceuticals Inc
$21.38
+0.09%
HEALTHCARE · Cap: $2.21B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 283% more annual revenue ($606.42M vs $158.18M). INSM leads profitability with a -2.1% profit margin vs -67.8%. INSM earns a higher WallStSmart Score of 39/100 (F).
DAWN
Avoid30
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 83.9% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
ROE of -22.7% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DAWN
The strongest argument for DAWN centers on Revenue Growth. Revenue growth of 83.9% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : DAWN
The primary concerns for DAWN are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
DAWN profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
DAWN is growing revenue faster at 83.9% — sustainability is the question.
DAWN generates stronger free cash flow (-18M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Day One Biopharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and markets targeted therapies for patients with genetically defined cancers. The company is headquartered in South San Francisco, California.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?